Evelyn Saba and colleagues found that ginsenoside Rg3 (20 mg/kg) could decrease the expression of pro-inflammatory mediators and cytokines including NO, IL-1β, IL-5, IL-13, and TNF-α, and levels of NLRP3 inflammasome in DSS-induced colitis mice (Saba et al., 2020). Here, IL5 is linked to colitis.